Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced a new version of Genedata Screener®, a comprehensive software system for high content data analysis. Screener version 9 celebrates ten years of industry leadership in delivering cost-efficient screening data management. It features an enhanced user interface for simultaneous processing of multiple dose-response curve assays and high content image display across the entire screening cascade. These features advance the speed and accuracy of all plate-based screening at pharmaceutical companies, specialized contract research organizations, and academic screening centers. Out-of-the-box integration with leading image store solutions creates a cost-efficient HCS data management infrastructure. Genedata, a sponsor of Cambridge Healthtech Institute’s 8th Annual High Content Analysis conference, will demonstrate the new Genedata Screener at Booth 28 (January 11 – 14; Fairmont Hotel).
“HCS has come of age. It has evolved from the domain of scientific experts to a broad application in life science research, which is fueled by a larger portfolio of affordable instruments and easier-to-use image analysis packages specific to experimental needs,” noted Dr. Othmar Pfannes, CEO of Genedata. “Genedata Screener 9 addresses this market shift with innovations in integration and visualization.
“With ten years of best practices built-in and five years specifically supporting high content data, Screener 9 is a proven enterprise hub for all plate-based screening data, with unmatched support for HCS data analysis,” continued Pfannes. “It integrates across instruments as well as HCS image analysis packages and image management systems. This integration plus enhanced visualization capabilities help to standardize and extend HCS data analysis across an organization while improving productivity without increasing data analysis cost.”
Innovations in Visualization and Integration
A modular system that supports the complete hit-to-lead process on a single platform, Genedata Screener scales from single plates to screens of millions of compounds. All industry-standard screening result calculations are incorporated into the system, which creates a single access point to data and images for downstream applications.
Genedata Screener 9 brings improved HCS image access and display with on-demand drill-down to original HCS images during dose-response analysis. New visualizations display complex images from multi-channeled HCS experiments including composites, masks, and overlays. They serve the in-depth qualification and systematic analysis of compound effects on cellular phenotypes. Specific enhancements include:
Genedata Screener version 9 is available now and shipping directly from Genedata.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.